RxDoctor Payments Data

David Lemons, DO

Interventional Cardiology · Palmer, AKNPI 1932338753

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (51.7%), food and beverage and education — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Abbott at 48.9% of the total. 2025 is the largest year on record at $2,668, more than ten times the $148 reported in 2019.

$6,779in general payments, 2019–2025

Across 147 payments — averaging $46.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Medtronic$2K
  • Novartis$420
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$178
  • E.r. Squibb & Sons, L.L.C.$153
  • Boehringer Ingelheim$147
  • plus $1K from 19 others

What the payments were for

  • Travel & lodging$3,50652%
  • Food & beverage$3,21847%
  • Education$561%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few interventional cardiology providers in Alaskato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$93,120
Medicare patients
645
Services billed
1,418

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban146$100,022
Repatha SureclickEvolocumab28$19,692
JardianceEmpagliflozin29$19,492
FarxigaDapagliflozin Propanediol18$15,537
EntrestoSacubitril/Valsartan18$11,854
Praluent PenAlirocumab15$9,246
Ranolazine ErRanolazine26$3,408
Bumetanide13$1,193
Losartan Potassium125$737
Atorvastatin Calcium97$663
Potassium Chloride45$662
Carvedilol95$604
Ezetimibe37$584
Valsartan21$516
Isosorbide Mononitrate ErIsosorbide Mononitrate53$488

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$45$100,022146 claims
Boehringer IngelheimJardiance$147$19,49229 claims
AstraZenecaFarxiga$97$15,53718 claims
NovartisEntresto$420$11,85418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few interventional cardiology providers in Alaskaon file to place this against a meaningful peer group, so we don't.

Other interventional cardiology in Palmer

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →